Business Wire

H2SITE

17.11.2022 09:01:40 CET | Business Wire | Press release

Share
H2SITE inaugurates the first production plant for palladium alloy membranes to obtain hydrogen

Hydrogen takes a new step as a for the energy transition thanks to H2SITE, which has launched the world's first membrane manufacturing plant to obtain hydrogen from ammonia or methanol, and separate hydrogen from low concentration gas blends. The new facility will industrialize the production of membranes, the technological heart of H2SITE, used in the construction of hydrogen production reactors and separators. Similar membranes made of palladium alloys had been so far very costly, fragile, and difficult to manufacture and scale. H2SITE has managed to overcome these obstacles.

Located in Loiu (Biscay Region, Spain), the new H2SITE plant has a production capacity of tens of thousands of membranes per year. For its construction, H2SITE has invested more than 3 million euros, which it plans to double in the coming years to increase production capacity.

“Once the first production line has been validated, our objective is to significantly increase the capacity of the plant, vertically integrate the manufacturing process of the membrane and build new plants to tackle new markets,” according to Andrés Galnares, CEO of H2SITE. "Our objective is to significantly increase the number of membranes produced each year for the next 3 years, which entails continuing to invest in production assets similar to those we have already installed and increasing their level of automation to further reduce our costs.”

In 2022, H2SITE has booked orders of more than 5 million euros. Galnares assures that the goal is to double that figure over the next year, reaching a workforce of more than 50 professionals.

Asier Rufino, CEO of TECNALIA Ventures and President of H2SITE, states that "at TECNALIA we have been working for 20 years on the development and scaling up of hydrogen technologies its entire value chain: production, distribution, transport, storage and end uses. Together with the Technical University of Eindhoven (TU/e), the technology H2SITE leverages on was created. Today, H2SITE has scaled the process, has industrialized it, and is managing to reduce its cost to be able to develop new use cases”.

This plant reflects the success of more than 10 years of collaboration initiated by TECNALIA and TU/e and supported by the Public Administration. H2SITE brings it to a new level with the industrialization of a disruptive process thanks to the help of investors who believe that technology is a critical enabler for the energy transition, such as ENGIE New Ventures, Breakthrough Energy Ventures, EQUINOR Ventures and institutional investors from the Basque Country Capital Riesgo País Vasco and Seed Capital Bizkaia. Along with the team that we have created, we cannot wish for better partners at this time," says Galnares.

The membrane separators and reactors will help provide hydrogen with high purity and limited cost, with focus on hard to abate industry sectors and heavy land and maritime mobility.

H2SITE is currently hiring in Europe. To learn more, follow H2SITE on LinkedIn.

About H2SITE

H2SITE was created in 2019 and has an exclusive technology of reactors separators for the conversion of different raw materials into hydrogen, among which are ammonia, methanol or synthetic gas, in addition to the separation of hydrogen from gaseous mixtures in low concentration.

https://www.h2site.eu/en/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005287/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye